The association between serum omentin level and bodyweight: A systematic review and meta-analysis of observational studies

Arab, Arman; Moosavian, Seyedeh Parisa; Hadi, Amir; Karimi, Elham; Nasirian, Maryam

doi:10.1016/j.clnesp.2020.06.014

Cited by 13 publications

(12 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, low circulating ITLN1 levels in people with impaired glucose regulation and untreated type 2 diabetes (52), women with metabolic syndrome secondary to polycystic ovary syndrome (53), and Japanese men with a higher number of metabolic risk factors (54) as well as in women with gestational diabetes and BMI <30 (52) suggest that low ITLN1 may be a marker for the metabolic effects of obesity rather than obesity itself. Although a recent meta-analysis of studies examining the relationship between body weight and circulating ITLN1 levels found an overall effect, there was very high study heterogeneity (93%) and evidence of publication bias (55). Furthermore, subgroup analysis revealed that higher-quality studies suggested no relationship and that serum ITLN1 level was significantly lower in overweight but not obese individuals (55).…”

Section: Intelectin Obesity and Cancer Riskmentioning

confidence: 99%

“…This could indicate an interaction between cancer presence, adiposity, and intelectin. However, as noted above, the evidence base for an association between circulating ITLN1 and overweight/obesity is weak (55). Arjmand et al (12) also grouped studies based on average BMI values but did not consider the variation around the mean for several studies (7,9,22,28,33,56).…”

Section: Intelectin Obesity and Cancer Riskmentioning

confidence: 99%

See 1 more Smart Citation

The Emerging Role of Intelectin-1 in Cancer

et al. 2022

View full text Add to dashboard Cite

BackgroundIntelectin (ITLN) is an adipokine with two homologs—ITLN1 and ITLN2—that has various physiological functions. Studies analyzing the relationship between ITLN and cancer are focused on ITLN1; the available literature on ITLN2 and cancer is limited. This review aims to evaluate the role of ITLN1 in cancer without imposing any inclusion criteria, to examine pro- and anticancer roles for ITLN1 and to discuss whether the relationship between ITLN and cancer is mediated by obesity.FindingsOverall, ITLN1 level was highly variable in cancer patients but different from healthy individuals. Compared with control groups, patients with gastrointestinal and prostate cancer showed increased concentrations of circulating ITLN1, while patients with gynecological, breast, bladder, and renal cancer had lower ITLN1 levels. Several studies also evaluated tissue and tumor expression of ITLN1. In gastrointestinal cancer, ITLN1 was increased in tumor tissue compared with adjacent healthy tissue and elevated in the visceral adipose tissue of patients compared with controls. Consequently, the high levels of circulating ITLN1 might be determined by the tumor and by the cancer-associated weight loss in gastrointestinal cancer. ITLN1 can activate the phosphoinositide-3-kinase-protein kinase B/Akt (PI3K/Akt) pathway. The improper regulation of this pathway may contribute to a series of cellular events that favor tumor development and progression. Obesity has been linked with an increased risk of developing some cancers. Indeed, low circulating ITLN1 levels may be a marker of the metabolic effects of obesity, rather than obesity per se, and might contribute to a deregulation of the PI3K/Akt pathway.ConclusionsITLN1 could be associated with cancer formation and progression. Since circulating ITLN1 levels are highly variable and differ between cancer types, the local tumor production of ITLN1 could be more relevant in determining malignant behavior. Future research should aim to identify the source of ITLN1 variability, to understand the differences in ITLN1 between distinct tumor types, and to further explore the signaling pathways through which this adipokine influences cancer biology.

show abstract

Section: Intelectin Obesity and Cancer Riskmentioning

confidence: 99%

Section: Intelectin Obesity and Cancer Riskmentioning

confidence: 99%

The Emerging Role of Intelectin-1 in Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Moreover, malnutrition is common in dialysis patients, 38 which also contributes to a higher plasma omentin-1 level. 18 , 39 , 40 …”

Section: Discussionmentioning

confidence: 99%

Omentin-1 Levels and Outcomes in Incident Peritoneal Dialysis Patients

Than¹,

Chan²,

Kwan³

et al. 2023

Kidney Medicine

View full text Add to dashboard Cite

“…In the present study, omentin-1 serum concentrations were decreased in CAD patients. Previous meta-analyses demonstrated that serum omentin-1 concentration was independently and negatively associated with CAD and reduced in obese individuals (Agasthi et al, 2015;Arab et al, 2020). Researchers who performed studies on patients with type 2 diabetes mellitus suggest that decreased omentin-1 level may be an independent risk factor for arteriosclerosis and carotid plaque formation in these patients (Yoo et al, 2011;Nishimura et al, 2019;Biscetti et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

FABP4 and omentin-1 gene expression in epicardial adipose tissue from coronary artery disease patients

et al. 2021

View full text Add to dashboard Cite

Omentin-1 and fatty acid-binding protein 4 (FABP4) are adipose tissue adipokines linked to obesity-associated cardiovascular complications. The aim of this study was to investigate epicardial adipose tissue (EAT) omentin-1 and FABP4 gene expression in obese and non-obese patients with coronary artery disease (CAD). Omentin-1 and FABP4 mRNA levels in EAT and paired subcutaneous adipose tissue (SAT) as well as adipokine serum concentrations were assessed in 77 individuals (61 with CAD; 16 without CAD (NCAD)). EAT FABP4 mRNA level was decreased in obese CAD patients when compared to obese NCAD individuals (p=0.001). SAT FABP4 mRNA level was decreased in CAD patients compared to NCAD individuals without respect to their obesity status (p=0.001). Omentin-1 mRNA level in EAT and SAT did not differ between the CAD and NCAD groups. These findings suggest that omentin-1 gene expression in adipose tissue is not changed during CAD; downregulated FABP4 gene expression in SAT is associated with CAD while EAT FABP4 gene expression is decreased only in obesity-related CAD.

show abstract

The association between serum omentin level and bodyweight: A systematic review and meta-analysis of observational studies

Cited by 13 publications

References 66 publications

The Emerging Role of Intelectin-1 in Cancer

The Emerging Role of Intelectin-1 in Cancer

Omentin-1 Levels and Outcomes in Incident Peritoneal Dialysis Patients

FABP4 and omentin-1 gene expression in epicardial adipose tissue from coronary artery disease patients

Contact Info

Product

Resources

About